Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01990443 · ClinicalTrials.gov registry record · Phase 1

Absolute Bioavailability of Reslizumab in Healthy Subjects

A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target

NCT01990443: Completed Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.

NCT01990443 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 75 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01990443, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target

Study Summary

The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants

Primary Outcome

Absolute bioavailability calculated as (AUC0-∞)sc/(AUC0-∞)

Interventions

  • DRUG Reslizumab IV
  • DRUG Reslizumab SC

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2013-06
Est. Completion 2014-03
Phase Phase 1

What the finished NCT01990443 record still lists

NCT01990443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% higher).

The record links to 0 conditions, and to 2 interventions - of which Reslizumab IV is the first listed.

NCT01990443 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01990443 about?

NCT01990443 is a clinical study titled "Absolute Bioavailability of Reslizumab in Healthy Subjects". The primary objective of this study is to assess the absolute bioavailability of reslizumab following administration of a single subcutaneous (sc) dose to healthy non-Japanese participants

What is the current status of trial NCT01990443?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-06. Estimated completion is 2014-03.

What interventions are being tested in trial NCT01990443?

The interventions under investigation include: Reslizumab IV (DRUG), Reslizumab SC (DRUG).

Who is sponsoring clinical trial NCT01990443?

This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01990443's enrollment target sits among peer trials

75 711th of 2000 higher than 1,276 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01990443, the US trial registry maintained by the National Library of Medicine. NCT01990443 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.